Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05036798
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Not yet recruiting
Phase Phase 2
Start date September 17, 2021
Completion date January 30, 2023